Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders
Jihad El Andari, Edith Renaud-Gabardos, Warut Tulalamba, et al.
Science Advances (2022) Vol. 8, Iss. 38
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Loss of epigenetic information as a cause of mammalian aging
Jae-Hyun Yang, Motoshi Hayano, Patrick Griffin, et al.
Cell (2023) Vol. 186, Iss. 2, pp. 305-326.e27
Open Access | Times Cited: 384
Split intein-mediated protein trans-splicing to express large dystrophins
Hichem Tasfaout, Christine L. Halbert, Timothy S. McMillen, et al.
Nature (2024) Vol. 632, Iss. 8023, pp. 192-200
Open Access | Times Cited: 16
Advanced Delivery Systems for Gene Editing: A Comprehensive Review from the GenE-HumDi COST Action Working group
Alessia Cavazza, Francisco J Molina-Estevez, Álvaro Plaza Reyes, et al.
Molecular Therapy — Nucleic Acids (2025) Vol. 36, Iss. 1, pp. 102457-102457
Open Access | Times Cited: 2
Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice
Yuan Zhou, Chen Zhang, Weidong Xiao, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 10
Duchenne Muscular Dystrophy Gene Therapy in 2023: Status, Perspective, and Beyond
Dongsheng Duan
Human Gene Therapy (2023) Vol. 34, Iss. 9-10, pp. 345-349
Open Access | Times Cited: 21
CRISPR-Editing Therapy for Duchenne Muscular Dystrophy
Francesco Chemello, Eric N. Olson, Rhonda Bassel‐Duby
Human Gene Therapy (2023) Vol. 34, Iss. 9-10, pp. 379-387
Open Access | Times Cited: 18
Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and Immunosuppression
Hildegund C.J. Ertl
Drugs (2023) Vol. 83, Iss. 4, pp. 287-298
Closed Access | Times Cited: 17
Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy
Sergio Muñoz, Joan Bertolin, Verónica Jiménez, et al.
Molecular Metabolism (2024) Vol. 81, pp. 101899-101899
Open Access | Times Cited: 7
Structure-guided AAV capsid evolution strategies for enhanced CNS gene delivery
Trevor J. Gonzalez, Aaron Mitchell-Dick, Leo O. Blondel, et al.
Nature Protocols (2023) Vol. 18, Iss. 11, pp. 3413-3459
Closed Access | Times Cited: 13
Gene therapy for genetic diseases: challenges and future directions
Beibei QIE, Jingsheng Tuo, Feilong Chen, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access
Preclinical development of genome editing to treat Duchenne muscular dystrophy by exon skipping
Made Harumi Padmaswari, Shilpi Agrawal, Christopher E. Nelson
Journal of Neuromuscular Diseases (2025)
Closed Access
Progress in Bioengineering of Myotropic Adeno-Associated Viral Gene Therapy Vectors
Jixin Liu, Teng Wei Koay, Olena Maiakovska, et al.
Human Gene Therapy (2023) Vol. 34, Iss. 9-10, pp. 350-364
Closed Access | Times Cited: 12
Gene therapy for heart failure and cardiomyopathies
Alessia Argirò, Jeffrey Ding, Eric Adler
Revista Española de Cardiología (English Edition) (2023) Vol. 76, Iss. 12, pp. 1042-1054
Open Access | Times Cited: 12
Comparative in vivo characterization of newly discovered myotropic adeno-associated vectors
Jacqueline Ji, Elise Lefebvre, Jocelyn Laporte
Skeletal Muscle (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Delivery of genetic medicines for muscular dystrophies
Yulia Chulanova, Dan Peer, Dan Peer
Cell Reports Medicine (2025) Vol. 6, Iss. 1, pp. 101885-101885
Open Access
ESGCT 31st Annual Congress In collaboration with SITGEC Rome, Italy October 22–25, 2024 Abstracts

Human Gene Therapy (2025) Vol. 36, Iss. 3-4, pp. e129-e557
Closed Access
Systemic Delivery of AAV5, AAV8, and AAV9 Packaging a C5-12-Micro-dystrophin-Flag Expression Cassette in Non-Human Primates
Mengping Liu, Edwin H. Cook, Yan‐Shan Dai, et al.
Molecular Therapy — Methods & Clinical Development (2025) Vol. 33, Iss. 1, pp. 101411-101411
Open Access
Improved Recombinant Adeno-Associated Viral Vector Production via Molecular Evolution of the Viral Rep Protein
Thomas Steininger, Veronika Öttl, Linda E. Franken, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1319-1319
Open Access
AAV capsids target muscle resident cells with different efficiencies - a comparative study between AAV8, AAVMYO and AAVMYO2
Timothy J McGowan, Nicolas Lewerenz, Eleonora Maino, et al.
Molecular Therapy — Methods & Clinical Development (2025) Vol. 33, Iss. 2, pp. 101451-101451
Open Access
Current limitations of gene therapy for rare pediatric diseases: Lessons learned from clinical experience with AAV vectors
Antoine Gardin, Giuseppe Ronzitti
Archives de Pédiatrie (2023) Vol. 30, Iss. 8, pp. 8S46-8S52
Closed Access | Times Cited: 10
Combining CRISPR-Cas-mediated terminal resolution with a novel genetic workflow to achieve high-diversity adenoviral libraries
Julian Fischer, Ariana Fedotova, Lena Jaki, et al.
Molecular Therapy — Methods & Clinical Development (2024) Vol. 32, Iss. 2, pp. 101241-101241
Open Access | Times Cited: 3
An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species
Ai Vu Hong, Laurence Suel, Eva Petat, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Muscle‐specific, liver‐detargeted adeno‐associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa−/− mice
Pauline Sellier, Pierre Vidal, Benjamin Bertin, et al.
Journal of Inherited Metabolic Disease (2023) Vol. 47, Iss. 1, pp. 119-134
Open Access | Times Cited: 8
Terapia génica para la insuficiencia cardiaca y las miocardiopatías
Alessia Argirò, Jeffrey Ding, Eric Adler
Revista Española de Cardiología (2023) Vol. 76, Iss. 12, pp. 1042-1054
Open Access | Times Cited: 8
Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy
Jakob Shoti, Keyun Qing, Geoffrey D. Keeler, et al.
Molecular Therapy — Methods & Clinical Development (2023) Vol. 31, pp. 101147-101147
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top